Characteristic | initial genome screen | focused screen | Difference between groups (P) | ||
---|---|---|---|---|---|
 | LGG-1 | HGG-1 | LGG-2 | HGG-2 |  |
 | (n = 90) | (n = 90) | (n = 90) | (n = 90) |  |
Age at RT | Â | Â | Â | Â | Â |
Mean ± SD | 59.7 ± 14.6 | 59.7 ± 11.5 | 62.5 ± 12.8 | 59.5 ± 11.1 | 0.434 |
Range | 26-89 | 38-83 | 38-88 | 21-79 | Â |
Family history of cancer | 33 (36.7%) | 23 (25.6%) | 42 (46.7%) | 37 (41.1%) | 0.129 |
Cancer type | Â | Â | Â | Â | Â |
Breast | 42 | 7 | 42 | 7 | Â |
Cervical | 15 | 27 | 15 | 27 | Â |
Esophageal | 4 | 15 | 4 | 15 | Â |
Head and neck | 10 | 30 | 9 | 31 | Â |
Lung | 18 | 10 | 19 | 9 | Â |
Prostate | 1 | 1 | 1 | 1 | Â |
TNM classification | Â | Â | Â | Â | Â |
T1 | 50 | 13 | 46 | 22 | Â |
T2 | 30 | 30 | 27 | 35 | Â |
T3 | 8 | 34 | 11 | 26 | Â |
T4 | 2 | 13 | 6 | 7 | Â |
N0 | 72 | 43 | 72 | 40 | Â |
N1 | 12 | 30 | 13 | 27 | Â |
N2 | 6 | 10 | 4 | 17 | Â |
N3 | 0 | 6 | 1 | 5 | Â |
N4 | 0 | 0 | 0 | 1 | Â |
M0 | 90 | 78 | 87 | 81 | Â |
M1 | 0 | 12 | 3 | 9 | Â |
Dose of radiotherapy (Gy)* | Â | Â | Â | Â | Â |
Breast | 49.6 ± 1.4 | 49.9 ± 0.6 | 0.602 | ||
Cervical | 50.2 ± 4.3 | 50.7 ± 3.9 | 0.704 | ||
Esophageal | 54.2 ± 11.3 | 50.7 ± 8.6 | 0.776 | ||
Head and neck | 65.0 ± 5.9 | 65.3 ± 3.9 | 0.8 | ||
Lung | 52.1 ± 8.9 | 51.4 ± 10.8 | 0.715 | ||
Grade of adverse event** | Â | Â | Â | Â | Â |
0 | 30 | 0 | 25 | 0 | Â |
1 | 60 | 0 | 65 | 0 | Â |
2 | 0 | 0 | 0 | 0 | Â |
3 | 0 | 84 | 0 | 74 | Â |
4 | 0 | 6 | 0 | 16 | Â |